Syros Pharmaceuticals (SYRS) Given a $28.00 Price Target by Oppenheimer Analysts

Oppenheimer set a $28.00 target price on Syros Pharmaceuticals (NASDAQ:SYRS) in a report published on Monday, January 8th. The firm currently has a buy rating on the stock. Oppenheimer also issued estimates for Syros Pharmaceuticals’ Q1 2018 earnings at ($0.59) EPS, Q2 2018 earnings at ($0.72) EPS, Q3 2018 earnings at ($0.74) EPS, Q4 2018 earnings at ($0.77) EPS, FY2018 earnings at ($2.83) EPS, FY2019 earnings at ($2.12) EPS, FY2020 earnings at ($0.19) EPS and FY2021 earnings at $1.70 EPS.

A number of other brokerages also recently commented on SYRS. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 11th. Roth Capital started coverage on shares of Syros Pharmaceuticals in a report on Monday, October 23rd. They set a neutral rating and a $15.00 target price for the company. Piper Jaffray Companies reaffirmed an overweight rating and set a $30.00 target price on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. JMP Securities raised shares of Syros Pharmaceuticals from a market perform rating to an outperform rating and set a $33.00 target price for the company in a report on Thursday, September 28th. Finally, ValuEngine downgraded shares of Syros Pharmaceuticals from a hold rating to a sell rating in a report on Friday, September 22nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. Syros Pharmaceuticals currently has an average rating of Buy and a consensus target price of $22.23.

Shares of Syros Pharmaceuticals (NASDAQ SYRS) traded down $0.14 on Monday, hitting $10.51. 257,300 shares of the stock were exchanged, compared to its average volume of 252,833. Syros Pharmaceuticals has a 52 week low of $6.30 and a 52 week high of $24.38. The company has a market cap of $276.38 and a P/E ratio of -6.04.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, meeting analysts’ consensus estimates of ($0.53). equities research analysts forecast that Syros Pharmaceuticals will post -2.12 earnings per share for the current year.

In other Syros Pharmaceuticals news, Director Srinivas Akkaraju acquired 109,774 shares of the business’s stock in a transaction on Thursday, December 14th. The stock was purchased at an average price of $9.03 per share, with a total value of $991,259.22. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jeremy P. Springhorn acquired 15,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was acquired at an average cost of $9.08 per share, with a total value of $136,200.00. The disclosure for this purchase can be found here. Insiders own 33.60% of the company’s stock.

Large investors have recently modified their holdings of the company. California State Teachers Retirement System raised its position in shares of Syros Pharmaceuticals by 131.3% in the 2nd quarter. California State Teachers Retirement System now owns 22,200 shares of the company’s stock valued at $357,000 after buying an additional 12,600 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Syros Pharmaceuticals by 157.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock valued at $483,000 after buying an additional 18,382 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Syros Pharmaceuticals in the 3rd quarter valued at approximately $975,000. Ark Investment Management LLC raised its position in shares of Syros Pharmaceuticals by 114.7% in the 2nd quarter. Ark Investment Management LLC now owns 17,705 shares of the company’s stock valued at $285,000 after buying an additional 9,460 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Syros Pharmaceuticals by 189.6% in the 2nd quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after buying an additional 250,507 shares in the last quarter. Institutional investors own 57.96% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Syros Pharmaceuticals (SYRS) Given a $28.00 Price Target by Oppenheimer Analysts” was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://baseballnewssource.com/markets/syros-pharmaceuticals-syrs-pt-set-at-28-00-by-oppenheimer/1818275.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.